[{"address1": "2000 Sierra Point Parkway", "address2": "Suite 400", "city": "Brisbane", "state": "CA", "zip": "94005", "country": "United States", "phone": "415 798 8589", "website": "https://www.tempesttx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.", "fullTimeEmployees": 17, "maxAge": 86400, "priceHint": 4, "previousClose": 2.01, "open": 1.96, "dayLow": 1.87, "dayHigh": 2.1086, "regularMarketPreviousClose": 2.01, "regularMarketOpen": 1.96, "regularMarketDayLow": 1.87, "regularMarketDayHigh": 2.1086, "beta": -2.637, "forwardPE": -1.1468927, "volume": 2775543, "regularMarketVolume": 2775543, "averageVolume": 1323195, "averageVolume10days": 3703900, "averageDailyVolume10Day": 3703900, "bid": 2.01, "ask": 2.04, "bidSize": 600, "askSize": 600, "marketCap": 45101120, "fiftyTwoWeekLow": 0.17, "fiftyTwoWeekHigh": 9.77, "fiftyDayAverage": 3.2705, "twoHundredDayAverage": 3.366985, "currency": "USD", "enterpriseValue": 33146048, "floatShares": 17786920, "sharesOutstanding": 22217300, "sharesShort": 1676660, "sharesShortPriorMonth": 1127331, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.075500004, "heldPercentInsiders": 0.00063, "heldPercentInstitutions": 0.27724, "shortRatio": 4.35, "shortPercentOfFloat": 0.0936, "impliedSharesOutstanding": 22217300, "bookValue": 0.929, "priceToBook": 2.1851451, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -29759000, "trailingEps": -1.72, "forwardEps": -1.77, "lastSplitFactor": "1:15", "lastSplitDate": 1624838400, "enterpriseToEbitda": -1.135, "52WeekChange": 0.66393447, "SandP52WeekChange": 0.26238096, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "TPST", "underlyingSymbol": "TPST", "shortName": "Tempest Therapeutics, Inc.", "longName": "Tempest Therapeutics, Inc.", "firstTradeDateEpochUtc": 1352730600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "d54d822e-cd83-39cb-b46d-5c9b6edb9502", "messageBoardId": "finmb_552715229", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.03, "targetHighPrice": 47.0, "targetLowPrice": 8.0, "targetMeanPrice": 18.6, "targetMedianPrice": 13.0, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 5, "totalCash": 32326000, "totalCashPerShare": 1.455, "ebitda": -29206000, "totalDebt": 20371000, "quickRatio": 3.024, "currentRatio": 3.133, "debtToEquity": 98.735, "returnOnAssets": -0.45207, "returnOnEquity": -1.88366, "freeCashflow": -16672375, "operatingCashflow": -26240000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]